ArticleFrontiers in medicine2026
Machine learning-driven risk assessment of severe
Article in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To construct and validate an interpretable machine learning model for early prediction of severe Methods: Clinical and immunological data of 402 pediatric MPP patients were randomly divided into a training set (70% for model tuning) and a held-out internal test set (30% for final evaluation). We systematically evaluated 113 algorithms based on data collected within 24 h of admission. Results: The Gradient Boosting Machine (GBM) demonstrated optimal performance, achieving an AUC of 0.805 (95% CI: 0.724-0.886) on the held-out internal test set. The model identified 16 core predictors: dyspnea, C-reactive protein (CRP), total T lymphocytes (CD3+), sputum plug formation (PB), CD3+CD4+CD8- T cells, CD3+CD56+NKT cells, LDH, IL-6, creatine kinase (CK), PCT, ALT, IgA, abnormal coagulation function (D-dimer), CK-MB, erythrocyte sedimentation rate (ESR), and MP-DNA load. SHapley Additive exPlanations (SHAP) analysis revealed that dyspnea, elevated CRP, and decreased T lymphocytes synergistically drive severe illness risk. Conclusion: The GBM-based model effectively predicts SMPP risk. Pending prospective multi-center validation, we plan to embed this transparent, data-driven tool into electronic medical record (EMR) systems to provide real-time early warning and individualized risk assessment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.